嘉和生物-B(06998.HK)與艾博生物訂立合作開發協議 共同開發mRNA產品及相關藥品
格隆匯6月24日丨嘉和生物-B(06998.HK)公吿,公司已與蘇州艾博生物科技有限公司訂立合作開發協議,共同開發具有全球創新性的mRNA產品及相關藥品。根據合作開發協議,集團的生物抗體開發平台將與艾博生物的mRNA技術平台結合,使集團與艾博生物能夠共同研發用於腫瘤治療的mRNA藥物。
作為一傢俱備藥物創新研發、臨牀前研究、臨牀開發、註冊、化學、生產和品質控制(CMC)開發及商業化生產能力的創新性、平台型、一體化公司,公司致力於開發具有全球權利且全球創新的優勢產品。目前,公司已成功搭建早期發現全球首創(FIC)╱ 全球最佳(BIC)、差異化、免疫腫瘤雙 ╱ 多特異性抗體研發平台。基於公司研發團隊對靶點抗分子生物學,細胞生物學及免疫學機制的深入理解,公司進行了多維度的FIC/BIC潛力的創新探索。目前已有數個FIC/BIC潛力的雙╱多抗分子發現專案啟動。
公司看好mRNA技術在醫藥領域的應用前景。通過本次合作,公司預計將充分利用公司具有高度差異化的FIC/BIC潛力的早期探索以及雙方各自平台的優勢,加快具有優勢潛力的用於腫瘤治療的mRNA藥物的發現與研發。
據悉,艾博生物成立於2019年初,是一家專注於信使核糖核酸(mRNA)藥物研發的創新型生物製藥公司。自成立以來,公司憑藉業界領先的具有自主智慧財產權的mRNA和納米遞送技術平台,建立了豐富的產品管線,涵蓋傳染病防治和腫瘤免疫等領域。2020年6月,公司聯合軍事科學院軍事醫學研究院、沃森生物共同研製的新型冠狀病毒mRNA疫苗,正式通過國家藥品監督管理局臨牀試驗批准,成為國內首個獲批開展臨牀試驗的mRNA疫苗。目前該疫苗已完成I期、II期臨牀研究,處於臨牀III期階段。公司已於2021年11月獲得新冠mRNA疫苗《藥品生產許可證》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.